Showing results (211-220 of 268) with videos related to

Sort By:
Pageof 27
AIDS (London, England)|May 12, 2000
Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study GroupT Puig, M Pérez-Olmeda, A Rubio, et al.
HIV Medicine|January 29, 2019
Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfectionJ J Malin, C Boesecke, C Schwarze-Zander, et al.
HIV Medicine|January 10, 2013
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB studyE Ribera, M Larrousse, A Curran, et al.
Molecular Pharmacology|January 12, 1999
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptorJ A Esté, C Cabrera, E De Clercq, et al.
HIV Medicine|December 16, 2014
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratioE Martínez, E Ribera, B Clotet, et al.
Hepato-Gastroenterology|December 5, 1998
Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factorsM A Del Pozo, J R Arias, J Pinilla, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 8, 2000
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)]J M Miró, A Antela, J Arrizabalaga, et al.
AIDS Care|November 30, 2006
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patientsC R Fumaz, J A Muñoz-Moreno, A L Ballesteros, et al.
AIDS (London, England)|December 1, 1996
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddCL Ruiz, J Romeu, J Martínez-Picado, et al.
The Journal of Infectious Diseases|June 3, 1999
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus loadA Arnó, L Ruiz, M Juan, et al.
Pageof 27